secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001493152-24-010152
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M
--------------------------------------------------------------------------------

- FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).
- Q4 2023 revenue $10.6M (+4% YoY); net income $3.5M ($1.65/shr) vs loss $2.8M ($2.16 loss/shr) in Q4 2022.
- Adjusted EBITDA for Q4 negative $3.2M (improved from negative $4.4M in prior year).
- Submitted sNDA to increase Ameluz use to 3 tubes for AK; PDUFA Oct 4, 2024. Phase 3 enrollment for sBCC completed.
- Restructured LSA to cut transfer price to 25% for 2024-2025; acquired patents for new portable PDT lamp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer